Veto Cell CAR‑T for Leukemia
Acute Lymphoblastic Leukemia
PreclinicalActive
Key Facts
About Cell Source
Innovative Veto Cell platform enabling donor‑free transplants and durable CAR‑T cancer therapies.
View full company profileTherapeutic Areas
Other Acute Lymphoblastic Leukemia Drugs
| Drug | Company | Phase |
|---|---|---|
| Acute Leukemia Panel (ALL) | 3B BlackBio | Commercial |
| Oncology Program (ALL) | IRBM | Pre-clinical |
| clonoSEQ (ALL, BM) | Adaptive Biotechnologies | FDA-Cleared |